Ring and nodular multiple sclerosis lesions: A retrospective natural history study

Neurology

Volumn 74, Issue 10, 2010, Pages 851-856

  Davis, M ^a   Auh, S ^a   Riva, M ^a   Richert, N D ^a   Frank, J A ^b,c   McFarland, H F ^a   Bagnato, F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 77949363891     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d31df5     Document Type: Article

References (27)

1. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;161:721-725.
2. Bastianello S, Pozzilli C, Bernardi S, et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990;40:591-595.
3. Hawkins CP, Munro PM, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990;113:365-378.
4. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications Brain 1990;113:1477-1489.
5. Harris JO, Frank JA, Patronas N, McFarlin DE, McFar-land HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555.
6. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
7. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
8. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lass-mann H. Inflammatory central nervous system demyelina-tion: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793.
9. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelina-tion. Ann Neurol 2000;47:707-717.
10. Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563-576.
11. Guttmann CR, Ahn SS, Hsu L, Kikinis R, Jolesz FA. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995;16:1481-1491.
12. Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995;16:69-77.
13. Petrella JR, Grossman RI, McGowan JC, Campbell G, Cohen JA. Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol 1996;17:1041-1049.
14. Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhancing T1-weighted and magnetization-transfer MR images. AJNR Am J Neuroradiol 1999;20:1939-1945.
15. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683.
16. Morgen K, Jeffries NO, Stone R, et al. Ring-enhancement in multiple sclerosis: marker of disease severity. Mult Scler 2001;7:167-171.
17. Zivadinov R, Bagnato F, Nasuelli D, et al. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci 2004;223:185-193.
18. Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol 2001;58:57-60.
19. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
21. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimes in MS: The Evidence Trial. Neurology 2002;59:1496-1506.
22. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in a primary progressive MS: an explanatory, randomized, controlled trial. Neurology 2003;60:44-51.
23. Chiu AW, Ehrmantraut M, Richert ND, et al. A case study on the effect of neutralizing antibodies to inter-feron beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 2007;150:61-67.
24. Gupta S, Solomon JM, Tasciyan TA, et al. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005;11:658-668.
25. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-1789.
26. Bagnato F, Butman J, Mora C, et al. Conventional magnetic resonance imaging features in patients with tropical spastic paraparesis. J Neurovirol 2005;11:525-534.
27. van den Elskamp IJ, Lembcke J, Dattola V, et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 2008;14:764-769.